OCUL
Ocular Therapeutix, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-05
Figures on this page computed 2026-11-08 12:40 UTC
Last close
7.14USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-05
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-05
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
-511.9%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
-417.5%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
0.12Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Price is the furthest below its sector's middle: 0.27 against 0.38 on the market's range.
- Growth24.4%55 of 100, above its sector
- Returns on capital-40.6%19 of 100, below its sector
- Margins87.3%29 of 100, below its sector
- Price1.9x27 of 100, below its sector
- Safety0.1279 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 0 of 1- Profit on each unit of sales-512%-1,115%Ahead
Higher is better here.
- Return on the capital it usesn/an/an/a
Higher is better here.
- Sales growth over five years24.5%n/an/a
Higher is better here.
- Debt against equity0.12n/an/a
Lower is better here.
- Gross margin87.4%n/an/a
Higher is better here.
- Price against earningsn/an/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Taysha Gene Therapies, Inc., OCUL is behind on 0 of 1 measures.
Against Taysha Gene Therapies, Inc., OCUL is behind on 0 of 1 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-05
Profit on each unit of sales-511.9%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD
Sales growth over five years24.4%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD
Debt against equity0.12
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD
Gross margin87.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD
Price against earningsn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-010664
- Reported in
- USD